Recently the European Bank for induced pluripotent Stem Cells (EBiSC) announced the launch of its on-line catalogue of iPSCs for use in disease modeling and pre-clinical research. The cell lines were created and deposited by EBiSC partner labs and a broad range of external organisations.
Upcoming efforts will introduce to the bank a large number of Parkinson’s and Alzheimer’s Disease lines, as well as lines for diabetes, cardiovascular research, muscular dystrophies, neuropathic pain, and more. These new lines will be produced through external collaborations, as well as cell line creation within the EBiSC.
Specifically, EBiSC announced:
EBiSC, the European Bank for induced pluripotent Stem Cells announces the public launch of its on-line catalogue of induced Pluripotent Stem Cells (iPSCs) which are available to academic and commercial scientists for use in disease modeling and other forms of pre-clinical research. (https://cells.ebisc.org). The initial collection of iPSCs available from the catalogue have been generated from a wide range of donors representing either specific disease backgrounds or healthy control donors. The catalogue has been created by the EBiSC consortium – a public-private partnership project supported by the Innovative Medicines Initiative (IMI), of 27 organisations, comprising pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA), small & medium-sized enterprises (SMEs) and academic institutions (www.ebisc.eu).
For the EBiSC iPSC catalogue, see https://cells.ebisc.org
For further information on EBiSC and the project partners see www.ebisc.eu.
For more information on the Innovative Medicines Initiative (IMI), visit www.imi.europa.eu
So, just a question here – do the universities give up all of their rights to the cell lines they generate and provide or are they included in any downstream revenues that pharma derive from their lines, as would be normal for a university licensing deal?